Criteria to qualify for study: Drug used in study:
  • IPSS-R intermediate /high/very high risk MDS OR CMML

MDS 21

Phase 3, randomized, controlled, open label, clinical study of Pevonedistat plus Azacitidine versus single agent Azacitidine as first-line treatment for patients with higher risk. Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia.